← Back to Clinical Trials
Recruiting NCT05037370

NCT05037370 CONTOURA vs WFO Ablation PRK & LASIK

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05037370
Status Recruiting
Phase
Sponsor 59th Medical Wing
Condition Refractive Surgery
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2021-04-22
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2021-04-22 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.

Eligibility Criteria

Inclusion Criteria: * Meet requirements for PRK or LASIK i.e., Stable \<= .5 D change MRSE) * DOD beneficiaries age 21-50 years * Local pts (w/i 60 mi) who will be in the area for at least 6 months post surgery * Willing to complete all required follow-up visits Exclusion Criteria: * No meeting requirements for PRK or LASIK * Desiring monovision treatment * Anisometropia \>2D spherical equivalent * Prior ocular surgeries / trauma / problem * History of dry eyes * Hyperopia * Mixed astigmatism * Inability to capture VARIO topolyzer scans * Pregnant (or who plans to be within 6 months after surgery) * Breastfeeding any time during the study * History of herpetic disease

Contact & Investigator

Central Contact

JOSE E CAPO-APONTE, OD, PhD

✉ Jose.E.CapoAponte.ctr@health.mil

📞 210-292-2554

Principal Investigator

CHARISMA B EVANGELISTA, MD

PRINCIPAL INVESTIGATOR

59th Medical Wing

Frequently Asked Questions

Who can join the NCT05037370 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Refractive Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05037370 currently recruiting?

Yes, NCT05037370 is actively recruiting participants. Contact the research team at Jose.E.CapoAponte.ctr@health.mil for enrollment information.

Where is the NCT05037370 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT05037370 clinical trial?

NCT05037370 is sponsored by 59th Medical Wing. The principal investigator is CHARISMA B EVANGELISTA, MD at 59th Medical Wing. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology